Zhang K, Zeng M, Li YJ, Wu HF, Wu JC, Zhang ZS, Zheng JF, Lv YF. Antibody and complement levels in patients with hypersplenism associated with cirrhotic portal hypertension and therapeutic principles. World J Clin Cases 2022; 10(36): 13208-13215 [PMID: 36683645 DOI: 10.12998/wjcc.v10.i36.13208]
Corresponding Author of This Article
Yun-Fu Lv, Doctor, MD, PhD, Academic Research, Chief Doctor, Professor, Research Scientist, Surgeon, Department of General Surgery, Hainan General Hospital, No. 19 Xiuhua Road, Xiuyin District, Haikou 570311, Hainan Province, China. yunfu_lv@126.com
Research Domain of This Article
Immunology
Article-Type of This Article
Retrospective Cohort Study
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Clin Cases. Dec 26, 2022; 10(36): 13208-13215 Published online Dec 26, 2022. doi: 10.12998/wjcc.v10.i36.13208
Antibody and complement levels in patients with hypersplenism associated with cirrhotic portal hypertension and therapeutic principles
Kun Zhang, Min Zeng, Ye-Juan Li, Hong-Fei Wu, Jin-Cai Wu, Zhen-Sheng Zhang, Jin-Fang Zheng, Yun-Fu Lv
Kun Zhang, Min Zeng, Department of Geriatric Center, Hainan General Hospital, Haikou 570311, Hainan Province, China
Ye-Juan Li, Reproductive Medicine Center, Maternal and Child Health Care Hospital of Hainan Province, Haikou 570311, Hainan Province, China
Hong-Fei Wu, Jin-Cai Wu, Zhen-Sheng Zhang, Jin-Fang Zheng, Yun-Fu Lv, Department of General Surgery, Hainan General Hospital, Haikou 570311, Hainan Province, China
Author contributions: Zhang K, Zeng M, Li YJ, Wu JC, Zheng JF and Lv YF contributed equally to this work; Lv YF was responsible for project design and thesis writing; Zhang K and Li YJ were responsible for implementation and statistical information; Wu JC, Zheng JF and Zeng M were responsible for data and statistical information collection; Wu HF and Zhang ZS participated in data collection and registration; all authors have read this article and consent to publication.
Supported byHainan Provincial Department of Science and Technology, Qiongke[2020]256.
Institutional review board statement: The patient data and research content submitted in this project comply with relevant laws and regulations. The study was approved for implementation by the Ethics Committee of Hainan General Hospital, approval No: Med Eth Re [2020] 086.
Conflict-of-interest statement: All authors report no relevant conflicts of interest for this article.
Data sharing statement: All data generated or analyzed during this study were included in this published article.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Yun-Fu Lv, Doctor, MD, PhD, Academic Research, Chief Doctor, Professor, Research Scientist, Surgeon, Department of General Surgery, Hainan General Hospital, No. 19 Xiuhua Road, Xiuyin District, Haikou 570311, Hainan Province, China. yunfu_lv@126.com
Received: September 16, 2022 Peer-review started: September 16, 2022 First decision: October 19, 2022 Revised: October 30, 2022 Accepted: November 30, 2022 Article in press: November 30, 2022 Published online: December 26, 2022 Processing time: 101 Days and 7.1 Hours
ARTICLE HIGHLIGHTS
Research background
The antibody and complement levels in patients with cirrhosis and hypersplenism due to portal hypertension are not clear, which affects the diagnosis and treatment to some extent.
Research motivation
There are no studies determining the levels of immunoglobulins (Ig) and complements in patients with hypersplenism due to cirrhosis and portal hypertension, which affects the diagnosis and treatment.
Research objectives
To investigate the antibody (Ig) and complement levels in patients with hypersplenism due to liver cirrhosis and portal hypertension and how to treat them.
Research methods
The levels of IgA, IgG, IgM, C3 and C4 were determined and compared in 119 patients with confirmed hypersplenism and 128 control patients.
Research results
The levels of IgA and IgG in the hypersplenism group were significantly higher than those in the control group (P < 0.001). The levels of C3 and C4 in the hypersplenism group were significantly lower than those in the control group (P < 0.001). The worse the liver function was, the higher the IgA and IgG levels were (P < 0.001) and the lower the C3 and C4 levels were (P < 0.001).
Research conclusions
Antibodies in patients with liver cirrhosis and portal hypertension and hypersplenism were significantly increased, while complements (C3 and C4) were significantly decreased. Both the increase of antibody and the decrease of complement are related to the damage of liver function.
Research perspectives
It is important to know the antibody (Ig) and complement levels of patients with hypersplenism due to cirrhosis and portal hypertension. Anti-hepatitis virus and liver function protection should be strengthened in treatment.
